Skip to main content

and
Your search also matched 10 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Enhancing pediatric access to cell and gene therapies

Include preview-only content
  1. Article

    Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

    Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen receptor (CAR) T cell therapies targeting CD19 experience disease progression, and neurotoxicity remains a challenge. Biom...

    Zinaida Good, Jay Y. Spiegel, Bita Sahaf, Meena B. Malipatlolla in Nature Medicine (2022)

  2. Article

    Open Access

    CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

    Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL)...

    Jay Y. Spiegel, Shabnum Patel, Lori Muffly, Nasheed M. Hossain, Jean Oak in Nature Medicine (2021)